Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 19/20 | 0.66 |
| ▸ | JAK3 | P52333 | 18/20 | 0.66 |
| ▸ | BTK | Q06187 | 16/20 | 0.66 |
| ▸ | EGFR | P00533 | 10/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20867957 | 0.95 | JAK3 (0.71) | LCKJAK3BTKEGFR | |
| SCHEMBL18884600 | 0.93 | LCK (0.74) | LCKJAK3BTKEGFR | |
| SCHEMBL18884514 | 0.92 | BTK (0.70) | LCKJAK3BTKEGFR | |
| SCHEMBL18296401 | 0.90 | LCK (0.65) | LCKJAK3BTKEGFR | |
| SCHEMBL18884692 | 0.88 | LCK (0.73) | LCKJAK3BTKEGFR | |
| SCHEMBL18296166 | 0.88 | JAK3 (0.63) | LCKJAK3BTKEGFR | |
| SCHEMBL23484954 | 0.86 | BTK (0.60) | LCKJAK3BTKEGFR | |
| SCHEMBL16763899 | 0.85 | JAK3 (0.93) | LCKJAK3BTKEGFR | |
| SCHEMBL16764235 | 0.85 | JAK3 (0.93) | LCKJAK3BTKEGFR | |
| SCHEMBL21946812 | 0.84 | JAK3 (0.76) | LCKJAK3BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | LCK 3/4885JAK3 53/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.